Coronary revascularization with bypass surgery proves to be superior to drug eluting stents in the long term in preventing all-cause mortality in patients with diabetes mellitus (DM) and multivessel coronary disease (MVD), even 8 years after the procedure, the FREEDOM* Follow-On Study reveals.
Dapagliflozin reduced the risk of hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) who had established or multiple risk factors for atherosclerotic cardiovascular disease (CVD), according to results of the DECLARE-TIMI 58* trial presented at AHA 2018. However, it did not reduce the incidence of major adverse cardiovascular events (MACE)**.
Transfemoral transcatheter aortic valve replacement (TF-TAVR), compared with surgical aortic valve replacement (SAVR), is associated with a lower risk of early major stroke despite similar early-peaking (<1 day postprocedure) neurological risk profiles, according to a new study.
Prescription of antibiotic prophylaxis (AP) has decreased among all infective endocarditis (IE) risk groups, especially those at moderate risk, a recent study has shown. At the same time, there has been a significant increase in IE incidence among high-risk individuals, a borderline significant risk in moderate-risk individuals, and no change among those at low or unknown risk.
Ranolazine offers a cost-effective addition to standard-of-care (SoC), resulting in improved quality-adjusted life years (QALYs) in type 2 diabetes (T2D) patients with stable but symptomatic angina, reports a recent US study.
In patients diagnosed with atrial fibrillation (AF), late initiation of oral anticoagulant (OAC) therapy is common and is associated with a significantly increased risk of stroke, according to a study led by the Chinese University of Hong Kong (CUHK).
New drug applications approved by US FDA as of 1 - 15 Apr 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Treatment with rivaroxaban for 45 days after hospital discharge reduces symptomatic venous thromboembolism (VTE), but not VTE-related mortality, in medically ill patients, results of the MARINER trial have shown.
The survival benefits conferred by blood pressure (BP) and lipid-lowering medications persist even after more than a decade following the end of the original trial, according to results from the ASCOT* Legacy study.